Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl

Journal of Cardiac Failure

Volumn 20, Issue 12, 2014, Pages 953-958

  Chin, Melanie P ^a   Wrolstad, Danielle ^b   Bakris, George L ^c   Chertow, Glenn M ^d   De Zeeuw, Dick ^e   Goldsberry, Angie ^a   Linde, Peter G ^f   McCullough, Peter A ^g,h   McMurray, John J ⁱ   Wittes, Janet ^b   Meyer, Colin J ^a  

^a Reata Pharmaceuticals Inc   (United States)

^b University of Iowa   (United States)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f ABBVIE INC   (United States)

^g BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^h BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

B type natriuretic peptide; Bardoxolone methyl; chronic kidney disease; randomized controlled trial

Indexed keywords

BARDOXOLONE METHYL; BRAIN NATRIURETIC PEPTIDE; PLACEBO; METHYL 2-CYANO-3,12-DIOXOOLEAN-1,9-DIEN-28-OATE; OLEANOLIC ACID;

ANGIONEUROTIC EDEMA; ARTICLE; BENIGN TUMOR; BREAST DISEASE; CARDIOGENIC SHOCK; CARDIOMEGALY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DRUG SAFETY; DYSPNEA; EAR DISEASE; ENDOCRINE DISEASE; EYE DISEASE; GASTROINTESTINAL DISEASE; GENERALIZED EDEMA; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART RIGHT VENTRICLE FAILURE; HEMATOLOGIC DISEASE; HEPATOBILIARY DISEASE; HOSPITALIZATION; HUMAN; IMMUNOPATHOLOGY; INFECTION; INFESTATION; INJURY; INNER EAR DISEASE; INTOXICATION; KIDNEY DISEASE; LOBAR PNEUMONIA; LUNG CONGESTION; LUNG EDEMA; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MEDIASTINUM DISEASE; MENTAL DISEASE; METABOLIC DISORDER; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL DISORDER; PERICARDIAL EFFUSION; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RISK ASSESSMENT; SKIN DISEASE; THORAX DISEASE; UROGENITAL TRACT DISEASE; VASCULAR DISEASE; AGED; ANALOGS AND DERIVATIVES; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DRUG ADMINISTRATION; EARLY TERMINATION OF CLINICAL TRIAL; FEMALE; FOLLOW UP; MALE; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PATIENT SAFETY; REFERENCE VALUE; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EARLY TERMINATION OF CLINICAL TRIALS; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; OLEANOLIC ACID; PATIENT SAFETY; PREDICTIVE VALUE OF TESTS; REFERENCE VALUES; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84904041193     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2014.10.001     Document Type: Article

References (19)

1. Q.Q. Wu, Y. Wang, M. Senitko, C. Meyer, W.C. Wigley, and D.A. Ferguson Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARγ, and HO-1 Am J Physiol Renal Physiol 300 2011 F1180 F1192
2. D.-F. Lee, H.-P. Kuo, M. Liu, C-K. Chou, W. Xia, and Y. Du KEAP1 E3 ligase-mediated downregulation of NF-kappaB signaling by targeting IKKbeta Mol Cell 36 2009 131 140
3. A.T. Dinkova-Kostova, K.T. Liby, K.K. Stephenson, W.D. Holtzclaw, X. Gao, and N. Suh Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress Proc Natl Acad Sci U S A 102 2005 4584 4589
4. W.O. Osburn, and T.W. Kensler Nrf2 signaling: an adaptive response pathway for protection against environmental toxic insults Mutat Res 659 2008 31 39
5. M. Chin, C.-Y.I. Lee, J.-C. Chuang, R. Bumeister, W.C. Wigley, and S.T. Sonis Bardoxolone methyl analogs RTA 405 and dh404 are well tolerated and exhibit efficacy in rodent models of Type 2 diabetes and obesity Am J Physiol Ren Physiol 304 2013 F1438 F1446
6. Ma R, Bumeister R, Stidham R. Bardoxolone methyl (BARD) inhibits inflammatory signaling in cultured mesangial cells. Proceedings of the National Kidney Foundation Spring Clinical Meetings, April 13-17, 2010, Lake Buena Vista, FL.
7. Y. Ding, R.D. Stidham, R. Bumeister, I. Trevino, A. Winters, and M. Sprouse The synthetic triterpenoid, RTA 405, increases the glomerular filtration rate and reduces angiotensin II-induced contraction of glomerular mesangial cells Kidney Int 83 2013 845 854
8. M.A. Aminzadeh, S.A. Reisman, N.D. Vaziri, M. Khazaeli, J. Yuan, and C.J. Meyer The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease Xenobiotica 44 2014 570 578
9. P.E. Pergola, P. Raskin, R.D. Toto, C.J. Meyer, J.W. Huff, and E.B. Grossman Bardoxolone methyl and kidney function in CKD with type 2 diabetes N Engl J Med 365 2011 327 336
10. D. de Zeeuw, T. Akizawa, P. Audhya, G.L. Bakris, M. Chin, and H. Christ-Schmidt Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease N Engl J Med 369 2013 2492 2503
11. D. de Zeeuw, T. Akizawa, R. Agarwal, G.L. Bakris, M. Chin, and M. Krauth Rationale and trial design of Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON) Am J Nephrol 37 2013 212 222
12. H.J. Lambers Heerspink, G. Chertow, T. Akizawa, P. Audhya, G.L. Bakris, and A. Goldsberry Baseline characteristics in the Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus: The Occurrence of Renal Events (BEACON) trial Nephrol Dial Transplant 28 2013 2841 2850
13. L. Breiman, J.H. Friedman, R.A. Olshen, and C.J. Stone Classification and regression trees 1984 CRC Press Boca Raton 368
14. J.F.E. Mann, D. Green, K. Jamerson, L.M. Ruilope, S.J. Kuranoff, and T. Littke Avosentan for overt diabetic nephropathy J Am Soc Nephrol 21 2010 527 535
15. C. Klein, P. Noertersheuser, S. Mensing, N. Teuscher, C. Meyer, and E. Dumas Exposure-response analyses of bardoxolone methyl safety and efficacy and clinical trial simulations to inform phase III dose selection Nephrol Dial Transplant 27 2012 ii403
16. J.M. Vinson, M.W. Rich, J.C. Sperry, A.S. Shah, and T. McNamara Early readmission of elderly patients with congestive heart failure J Am Geriatr Soc 38 1990 1290 1295
17. P.A. McCullough, R.M. Nowak, J. McCord, J.E. Hollander, H.C. Hermann, and P.G. Steg B-Type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) multinational study Circulation 106 2002 416 422
18. J.A. De Lemos, D.K. McGuire, and M.H. Drazner B-Type natriuretic peptide in cardiovascular disease Lancet 362 2003 316 322
19. M. Chin, S. Reisman, G. Bakris, M. O'Grady, P.G. Linde, and P.A. McCullough Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl Am J Nephrol 39 2014 499 508